Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Analysis of hearing loss due to cis-diamminedichloroplatinum-II.

Literature DB >> 6539589

Analysis of hearing loss due to cis-diamminedichloroplatinum-II.

L G van Zeijl, E A Conijn, M Rodenburg, R A Tange, M P Brocaar.

Abstract

The difference in the hearing threshold before and after treatment with cis-diaminnedichloroplatinum (DDP) is analysed in 69 patients. Hearing loss due to DDP treatment is mainly limited to 8,000 Hz and the incidence is about 40%. The effect of DDP is dose-related, although even at the lowest dose 20% of the patients are affected. The age of the patients is not an important factor. Loss of hearing due to DDP treatment occurs independent of any pre-existent hearing loss although those patients with great pre-existent hearing loss do not show a further loss. Of the patients with hearing loss, 39% show a difference of 20 dB or more between the left and the right ear. Hearing loss due to DDP is of minor importance compared with many of the other side-effects of DDP.

Entities: Chemical Disease Species

Mesh：

Substances：
Cisplatin

Year: 1984 PMID： 6539589 DOI： 10.1007/bf00464252

Source DB: PubMed Journal: Arch Otorhinolaryngol ISSN： 0302-9530

11 in total

Analysis of hearing loss due to cis-diamminedichloroplatinum-II.

1. Effects of cis-diamminedichloroplatinum (NSC-119875) on hearing function in man.

2. Clinical trials of cis-diamminedichloroplatinum (NSC-119875).

3. Relation between psychophysical data and speech perception for hearing-impaired subjects. I.

4. Relations between auditory functions in normal hearing.

5. cis-Platinum ototoxicity.

6. Auditory toxicity effects of long-term cis-dichlorodiammineplatinum II therapy in genitourinary cancer patients.

7. Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration.

Review 8. Noble metal complexes in cancer chemotherapy.

9. Ototoxicity of cis-diamminedichloroplatinum (II): influence of dose, schedule and mode of administration.

10. High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis.

1. Evaluation of audiometric threshold shift criteria for ototoxicity monitoring.

2. The importance of high-tone audiometry in monitoring for ototoxicity.

3. Development of cis-platinum-induced hearing loss in guinea pigs.

4. Correlations between cis-platinum dosage and toxicity in a guinea pig model.

5. Early Physiological and Cellular Indicators of Cisplatin-Induced Ototoxicity.

6. Cisplatin is retained in the cochlea indefinitely following chemotherapy.

7. Ototoxicity and Platinum Uptake Following Cyclic Administration of Platinum-Based Chemotherapeutic Agents.

Review 8. Mass Cytometry Imaging for the Study of Human Diseases-Applications and Data Analysis Strategies.